Sunovion, Novartis ink licensing deal for inhaled COPD drugs

Novartis (NYSE:NVS) said today that it out-licensed its U.S. commercial rights for 3 inhaled chronic obstructive pulmonary disease drugs to Sunovion Pharmaceuticals. Novartis will commercialize the Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler inhalation powders outside of the U.S.

The Switzerland-based company will manufacture the powders for Sunovion, according to the agreement.

Get the full story at our sister site, Drug Delivery Business News.

The post Sunovion, Novartis ink licensing deal for inhaled COPD drugs appeared first on MassDevice.

from MassDevice http://ift.tt/2hhcXai